These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 18759353)

  • 21. Correlation between neuromelanin-sensitive MR imaging and (123)I-FP-CIT SPECT in patients with parkinsonism.
    Kuya K; Shinohara Y; Miyoshi F; Fujii S; Tanabe Y; Ogawa T
    Neuroradiology; 2016 Apr; 58(4):351-6. PubMed ID: 26779912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implementation of the European multicentre database of healthy controls for [(123)I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes.
    Albert NL; Unterrainer M; Diemling M; Xiong G; Bartenstein P; Koch W; Varrone A; Dickson JC; Tossici-Bolt L; Sera T; Asenbaum S; Booij J; Kapucu LÖ; Kluge A; Ziebell M; Darcourt J; Nobili F; Pagani M; Sabri O; Hesse S; Borght TV; Van Laere K; Tatsch K; la Fougère C
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1315-22. PubMed ID: 26780619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can spiral analysis predict the FP-CIT SPECT scan result in tremulous patients?
    Bajaj NP; Knöbel M; Gontu V; Bain PG
    Mov Disord; 2011 Mar; 26(4):699-704. PubMed ID: 21370257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: molecular imaging with 123I-FP-CIT SPECT.
    Schillaci O; Chiaravalloti A; Pierantozzi M; Di Pietro B; Koch G; Bruni C; Stanzione P; Stefani A
    Int J Mol Med; 2011 Nov; 28(5):881-6. PubMed ID: 21811760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand.
    Løkkegaard A; Werdelin LM; Friberg L
    Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1623-9. PubMed ID: 12458397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Diagnostic accuracy of FP-CIT SPECT in patients with parkinsonism].
    Ortega Lozano SJ; Martínez Del Valle Torres MD; Jiménez-Hoyuela García JM; Gutiérrez Cardo AL; Campos Arillo V
    Rev Esp Med Nucl; 2007; 26(5):277-85. PubMed ID: 17910836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 123I-FP-CIT SPECT and MRI Findings in a Patient With Parkinsonism After Fenpyroximate Intoxication.
    Kim KJ; Kim JM; Bae YJ; Song YS; Kim SE
    Clin Nucl Med; 2018 Jun; 43(6):e178-e179. PubMed ID: 29629914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes.
    Vlaar AM; de Nijs T; Kessels AG; Vreeling FW; Winogrodzka A; Mess WH; Tromp SC; van Kroonenburgh MJ; Weber WE
    Eur Neurol; 2008; 59(5):258-66. PubMed ID: 18264015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
    Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
    Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of dopaminergic function in frontotemporal dementia using I-FP-CIT single photon emission computed tomography.
    Sedaghat F; Gotzamani-Psarrakou A; Dedousi E; Arnaoutoglou M; Psarrakos K; Baloyannis I; Dimitriadis AS; Baloyannis SJ
    Neurodegener Dis; 2007; 4(5):382-5. PubMed ID: 17622781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistent Drug-Induced Parkinsonism in Patients with Normal Dopamine Transporter Imaging.
    Hong JY; Sunwoo MK; Oh JS; Kim JS; Sohn YH; Lee PH
    PLoS One; 2016; 11(6):e0157410. PubMed ID: 27294367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.
    O'Brien JT; Colloby S; Fenwick J; Williams ED; Firbank M; Burn D; Aarsland D; McKeith IG
    Arch Neurol; 2004 Jun; 61(6):919-25. PubMed ID: 15210531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical impact of correlative [123I]-FP-CIT brain imaging and neurological findings in suspect Parkinson's disease.
    Covelli EM; Brunetti A; Di Lauro A; Sullo P; Mazzarella G; Tedeschi E; Belfiore G
    Radiol Med; 2004 Oct; 108(4):417-25. PubMed ID: 15525895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
    Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
    Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced striatal [123 I]FP-CIT binding in SCA2 patients without parkinsonism.
    Varrone A; Salvatore E; De Michele G; Barone P; Sansone V; Pellecchia MT; Castaldo I; Coppola G; Brunetti A; Salvatore M; Pappatà S; Filla A
    Ann Neurol; 2004 Mar; 55(3):426-30. PubMed ID: 14991822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT.
    Marshall VL; Patterson J; Hadley DM; Grosset KA; Grosset DG
    Mov Disord; 2006 Dec; 21(12):2247-50. PubMed ID: 17078059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Shape analysis of 123I-N-omega-fluoropropyl-2-beta-carbomethoxy-3beta-(4-iodophenyl) nortropane single-photon emission computed tomography images in the assessment of patients with parkinsonian syndromes.
    Staff RT; Ahearn TS; Wilson K; Counsell CE; Taylor K; Caslake R; Davidson JE; Gemmell HG; Murray AD
    Nucl Med Commun; 2009 Mar; 30(3):194-201. PubMed ID: 19262280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The utility of dopamine transporter scans for diagnosing Parkinsonian disorders.
    Crotty GF; O’Corragain OA; Bogue C; Crotty J; O’Sullivan SS
    Ir Med J; 2018 May; 111(5):751. PubMed ID: 30489047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thiethylperazine-induced parkinsonism: in vivo demonstration of dopamine D2 receptors blockade.
    Briani C; Cagnin A; Chierichetti F; Tiberio M; Battistin L; Pizzolato G
    Eur J Neurol; 2004 Oct; 11(10):709-10. PubMed ID: 15469457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.